Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Prescription Drugs
💊 Drugs • 11,927 recalls
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Crystallization: Presence of visible particulate matter.
Crystallization: Presence of visible particulate matter.
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Presence of Foreign Substance: Foreign material found inside the vial.
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.